Stockscreener 앱 받기
225.39
0.06%
-0.10
전일 마감가:
$225.49
열려 있는:
$225.49
하루 거래량:
877.90K
Relative Volume:
0.66
시가총액:
$31.44B
수익:
$2.12B
순이익/손실:
$-309.19M
주가수익비율:
-98.68
EPS:
-2.2841
순현금흐름:
$93.57M
1주 성능:
-2.46%
1개월 성능:
+5.48%
6개월 성능:
+31.81%
1년 성능:
+45.21%
1일 변동 폭
$223.98
$228.71
1주일 범위
$221.84
$232.76
52주 변동 폭
$125.38
$246.90
Natera Inc Stock (NTRA) Company Profile
명칭
Natera Inc
전화
650-249-9090
주소
13011 MCCALLEN PASS, AUSTIN, CA
NTRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
225.44 | 31.44B | 2.12B | -309.19M | 93.57M | -2.2841 |
|
TMO
Thermo Fisher Scientific Inc
|
561.77 | 211.36B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
225.59 | 157.25B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
697.78 | 55.54B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
137.46 | 38.68B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
223.34 | 37.71B | 15.90B | 1.28B | 2.21B | 7.2842 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-10-27 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | 재개 | Wells Fargo | Equal Weight |
| 2025-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-08 | 재개 | Craig Hallum | Buy |
| 2024-02-20 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-11-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 개시 | Bernstein | Mkt Perform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 개시 | Stephens | Overweight |
| 2022-03-08 | 개시 | Goldman | Buy |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-09-28 | 개시 | Morgan Stanley | Overweight |
| 2020-09-17 | 개시 | SVB Leerink | Outperform |
| 2020-06-10 | 재개 | Piper Sandler | Overweight |
| 2020-05-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 개시 | JP Morgan | Neutral |
| 2018-07-05 | 재확인 | Piper Jaffray | Overweight |
| 2017-08-07 | 재확인 | Morgan Stanley | Overweight |
| 2016-11-10 | 재확인 | The Benchmark Company | Buy |
| 2016-05-23 | 재확인 | The Benchmark Company | Buy |
| 2016-05-11 | 재확인 | The Benchmark Company | Buy |
| 2016-04-19 | 개시 | The Benchmark Company | Buy |
| 2015-09-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2015-08-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 개시 | Robert W. Baird | Outperform |
| 2015-07-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 개시 | Piper Jaffray | Overweight |
| 2015-07-27 | 개시 | Wedbush | Neutral |
모두보기
Natera Inc 주식(NTRA)의 최신 뉴스
NTRA: Natera's Phase III Study Highlights Celecoxib's Efficacy i - GuruFocus
Study shows celecoxib improves survival in certain colorectal cancer patients - Investing.com India
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer - Yahoo Finance
Is Natera Inc. stock attractive after correctionJuly 2025 Opening Moves & Weekly Chart Analysis and Guides - Улправда
Thrivent Financial for Lutherans Cuts Stake in Natera, Inc. $NTRA - MarketBeat
Assenagon Asset Management S.A. Purchases 80,684 Shares of Natera, Inc. $NTRA - MarketBeat
Natera (NTRA) director and co-founder discloses stock gift and sales - Stock Titan
Dir Sheena Sells 3,070 ($696.9K) Of Natera Inc [NTRA] - TradingView — Track All Markets
Natera’s Signatera Test Gains Validation in Key Breast Cancer Study - AD HOC NEWS
Dir Sheena Files To Sell 9,210 Of Natera Inc [NTRA] - TradingView — Track All Markets
Natera, Inc.'s (NASDAQ:NTRA) Business Is Trailing The Industry But Its Shares Aren't - 富途牛牛
Solomon Moshkevich Sells 4,692 Shares of Natera (NASDAQ:NTRA) Stock - MarketBeat
Insider Selling: Natera (NASDAQ:NTRA) Director Sells 48,419 Shares of Stock - MarketBeat
Officer Moshkevich Acquires 17,684 Of Natera Inc [NTRA] - TradingView — Track All Markets
NATERA INC : JEFFERIES RAISES TARGET PRICE TO $275 FROM $230 - 富途牛牛
Natera’s cancer test improves risk assessment in breast cancer patients By Investing.com - Investing.com Nigeria
Natera, Inc. $NTRA Shares Bought by New England Research & Management Inc. - MarketBeat
Natera (NASDAQ: NTRA) I-SPY 2 study ties Signatera ctDNA status to 3-year DRFS, recurrence risk - Stock Titan
NeoGenomics (NEO): Assessing Valuation After Legal Win Over Natera and New Oncology Data Releases - simplywall.st
Jefferies raises Natera stock price target to $275 on oncology growth - Investing.com India
Barclays Raises Natera (NTRA) Price Target to $270 | NTRA Stock News - GuruFocus
NTRA: JP Morgan Raises Price Target to $260 with Overweight Rati - GuruFocus
Natera (NASDAQ:NTRA) Given New $260.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Natera dismisses appeal in patent case against NeoGenomics - Investing.com India
Natera dismisses appeal in patent case against NeoGenomics By Investing.com - Investing.com Australia
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litig - pharmiweb.com
NeoGenomics Says Natera Withdraws Appeal in Patent Case - marketscreener.com
Neogenomics announces that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation - marketscreener.com
Neogenomics Announces That Natera Has Voluntarily Withdrawn Its Appeal In Ongoing RaDaR Patent Litigation - TradingView — Track All Markets
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation - Business Wire
Marex Group plc Makes New Investment in Natera, Inc. $NTRA - MarketBeat
Castleark Management LLC Has $5.87 Million Stake in Natera, Inc. $NTRA - MarketBeat
Wells Fargo maintains Natera (NTRA) equal-weight recommendation - MSN
Natera (NTRA): Assessing Valuation After Strong Multi‑Year Share Price Rally - simplywall.st
Holocene Advisors LP Boosts Stake in Natera, Inc. $NTRA - MarketBeat
Fullerton Fund Management Co Ltd. Has $1.05 Million Holdings in Natera, Inc. $NTRA - MarketBeat
Natera, Inc. $NTRA Shares Bought by Nikko Asset Management Americas Inc. - MarketBeat
Natera, Inc. (NASDAQ:NTRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Engineers Gate Manager LP Sells 30,042 Shares of Natera, Inc. $NTRA - MarketBeat
GCM Grosvenor Holdings LLC Sells 6,475 Shares of Natera, Inc. $NTRA - MarketBeat
Gilder Gagnon Howe & Co. LLC Decreases Stake in Natera, Inc. $NTRA - MarketBeat
Bellevue Group AG Raises Stock Position in Natera, Inc. $NTRA - MarketBeat
AQR Capital Management LLC Boosts Holdings in Natera, Inc. $NTRA - MarketBeat
Officer Moshkevich Files To Sell 4,692 Of Natera Inc [NTRA] - TradingView — Track All Markets
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Exelixis (EXEL) and Natera (NTRA) - The Globe and Mail
Caption Management LLC Takes Position in Natera, Inc. $NTRA - MarketBeat
Natera (NTRA) Joins Phase II Breast Cancer Study with Innovative DNA Testing - GuruFocus
Maverick Capital Ltd. Reduces Position in Natera, Inc. $NTRA - MarketBeat
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer - Yahoo Finance
Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know - MSN
Dir Sheena Acquires 4,436 Of Natera Inc [NTRA] - TradingView — Track All Markets
Natera Inc (NTRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
0.02%
자본화:
|
볼륨(24시간):